Quick Answer
LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported Total Revenue of $0.00 for fiscal year 2013.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$6.08M -69.5% |
-$3.59M +29.5% |
-$5.09M +19.4% |
-$6.31M +6.2% |
-$6.73M -106.1% |
-$3.26M -33.8% |
| Diluted EPS | -$1.26 +20.8% |
-$1.59 +40.2% |
-$2.66 +33.3% |
-$3.99 | — | — |
| Total Assets | $12.73M +1011.6% |
$1.15M -73.4% |
$4.31M -22.5% |
$5.56M +9.2% |
$5.09M -2.6% |
$5.23M +95.7% |
| Cash and Equivalents | — | — | $4.20M -21.5% |
$5.35M +11.0% |
$4.82M -4.8% |
$5.07M +95.1% |
| Stockholders Equity | $9.66M +1068.3% |
$827.2K -79.3% |
$3.99M -22.7% |
$5.17M +7.8% |
$4.79M -4.4% |
$5.01M +105.9% |
| R&D Expense | $254.9K -64.9% |
$726.2K -19.1% |
$898.1K -33.4% |
$1.35M -22.3% |
$1.74M +41.9% |
$1.22M +49.1% |
| Operating Income | -$5.11M -43.0% |
-$3.57M +29.8% |
-$5.09M +19.3% |
-$6.31M +6.1% |
-$6.72M -105.7% |
-$3.27M -31.2% |
| Shares Outstanding | 8.79M +290.8% |
2.25M +0.0% |
2.25M +35.1% |
1.66M -87.9% |
13.75M +10.8% |
12.40M +11.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2013 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$1.98M | -100.8% | -155.3% |
| Diluted EPS | September 30, 2025 | -$0.33 | +25.0% | -13.8% |
| Total Assets | September 30, 2025 | $5.43M | +220.4% | +357.2% |
| Cash and Equivalents | March 31, 2024 | $3.41M | -16.5% | -18.8% |
| Stockholders Equity | September 30, 2025 | $4.91M | +259.4% | +654.0% |
| R&D Expense | September 30, 2025 | $50.7K | -86.0% | -16.4% |
| Operating Income | September 30, 2025 | -$1.80M | -83.2% | -132.5% |
| Shares Outstanding | September 30, 2025 | 5.70M | +153.6% | +106.9% |
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported Total Revenue of $0.00 for fiscal year 2013.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported Net Income of -$6.08 million for fiscal year 2025.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. showed a decrease of -69.5% in Net Income compared to the prior fiscal year.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported Diluted EPS of $1.26 per share (loss) for fiscal year 2025.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. showed an increase of +20.8% in Diluted EPS compared to the prior fiscal year.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported Total Assets of $12.73 million for fiscal year 2025.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. showed an increase of +1011.6% in Total Assets compared to the prior fiscal year.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported Cash and Equivalents of $4.20 million for fiscal year 2023.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. showed a decrease of -21.5% in Cash and Equivalents compared to the prior fiscal year.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported Stockholders Equity of $9.66 million for fiscal year 2025.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. showed an increase of +1068.3% in Stockholders Equity compared to the prior fiscal year.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported R&D Expense of $254.9 thousand for fiscal year 2025.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. showed a decrease of -64.9% in R&D Expense compared to the prior fiscal year.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported Operating Income of -$5.11 million for fiscal year 2025.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. showed a decrease of -43.0% in Operating Income compared to the prior fiscal year.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported Shares Outstanding of 8.79 million shares for fiscal year 2025.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. showed an increase of +290.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: